We are live on ! Find out more
OTLK icon

Outlook Therapeutics

73 hedge funds and large institutions have $45.5M invested in Outlook Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more capital inflows, than outflows

Capital inflows: $6.18M | Capital outflows: $3.9M

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

3% more funds holding

Funds holding: 71 → 73 (+2)

0.62% more ownership

Funds ownership: 10.72% → 11.34% (+0.62%)

Holders
73
Holders Change
+2
Holders Change %
+2.82%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
24
Reduced
21
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q1 2022 in Review

73 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2022, worth a combined $45.5M — up 39% from $32.7M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new OTLK positions and 9 closed out — a net gain of 4 holders — while 24 added to existing stakes and 21 trimmed.

The largest buyer was Vista Finance, opening a new position worth an estimated $1.54M. The largest seller was Two Sigma Investments, cutting an estimated $834K.

  • 73 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2022, up from 71 in Q4 2021.
  • Funds reported $45.5M of Outlook Therapeutics stock for Q1 2022, up 39% quarter-over-quarter.
  • 13 funds opened new Outlook Therapeutics positions in Q1 2022 and 9 closed out, a net change of +4 holders.
  • The largest Outlook Therapeutics buyer in Q1 2022 was Vista Finance, an estimated $1.54M added.
  • The largest Outlook Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $834K sold.

Based on aggregated 13F filings for Q1 2022.